Related references
Note: Only part of the references are listed.The efficacy of anlotinib instead of glucocorticoids for edema induced by brain metastases in NSCLC patients with anti-PD1/PDL-1 immunotherapy
Hongqing Zhuang et al.
NEURO-ONCOLOGY (2021)
Synergism between anti-angiogenic and immune checkpoint inhibitor drugs: A hypothesis
Ajit Venniyoor
MEDICAL HYPOTHESES (2021)
Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC
Tianqing Chu et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Severe depletion of peripheral blood dendritic cell subsets in obstructive sleep apnea patients: A new link with cancer?
Domenico Galati et al.
CYTOKINE (2020)
Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases
Wang Li et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer
Shiqiang Wang et al.
ONCOTARGETS AND THERAPY (2020)
Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells
Florian Klemm et al.
CELL (2020)
The Story of Angiogenesis Inhibitors in Non-small-cell Lung Cancer: The Past, Present, and Future
Nikhil Atul Shukla et al.
CLINICAL LUNG CANCER (2020)
An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancer
Georgios Tsakonas et al.
EUROPEAN JOURNAL OF CANCER (2020)
Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer
Yinli Yang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?
Sanjay Popat et al.
LUNG CANCER (2020)
Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients
Lupeng Qiu et al.
MEDICINE (2020)
Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic
N. Vilarino et al.
CANCER TREATMENT REVIEWS (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Treatment after progression in the era of immunotherapy
Salem Billan et al.
LANCET ONCOLOGY (2020)
Anti-angiogenesis: Opening a new window for immunotherapy
Feifei Guo et al.
LIFE SCIENCES (2020)
Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
Yuxiao Song et al.
FRONTIERS IN IMMUNOLOGY (2020)
Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression
Xiaomin Cai et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer
Sha Zhao et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck et al.
LANCET RESPIRATORY MEDICINE (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Ming Yi et al.
MOLECULAR CANCER (2019)
Vascular endothelial growth factor (VEGF) impairs the motility and immune function of human mature dendritic cells through the VEGF receptor 2-RhoA-cofilin1 pathway
Jinhua Long et al.
CANCER SCIENCE (2019)
Microenvironmental Regulation of Tumor Progression and Therapeutic Response in Brain Metastasis
Michael Schulz et al.
FRONTIERS IN IMMUNOLOGY (2019)
Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
B. Han et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Management of Brain Metastases in Non-Small-Cell Lung Cancer
Vinicius Ernani et al.
JOURNAL OF ONCOLOGY PRACTICE (2019)
Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements
Vaishali Aggarwal et al.
BIOMOLECULES (2019)
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors
Giovanni Fuca et al.
ESMO OPEN (2019)
Checkpoint inhibitors: 'raising the bar' also in brain metastases from non-small-cell lung cancer?
Sabrina Rossi et al.
IMMUNOTHERAPY (2018)
Increased vessel perfusion predicts the efficacy of immune checkpoint blockade
Xichen Zheng et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Emerging Trends in the Management of Brain Metastases from Non-small Cell Lung Cancer
Thomas M. Churilla et al.
CURRENT ONCOLOGY REPORTS (2018)
Targeting veGF/veGFR to Modulate Antitumor immunity
Ju Yang et al.
FRONTIERS IN IMMUNOLOGY (2018)
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK plus ) non-small-cell lung cancer: CNS efficacy results from the ALEX study
S. Gadgeel et al.
ANNALS OF ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
Thanyanan Reungwetwattana et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study
Shirish M. Gadgeel et al.
LUNG CANCER (2018)
Anti-angiogenic therapies in brain metastases
Anna S. Berghoff et al.
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY (2018)
Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study
Xinyang Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Lin Tian et al.
NATURE (2017)
Immune Regulation of Antibody Access to Neuronal Tissues
Akiko Iwasaki
TRENDS IN MOLECULAR MEDICINE (2017)
The Microenvironmental Landscape of Brain Tumors
Daniela F. Quail et al.
CANCER CELL (2017)
The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope
Pranshu Bansal et al.
FUTURE ONCOLOGY (2016)
Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets)
Jonathan W. Goldman et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
How Do Meningeal Lymhatic Vessels Drain the CNS?
Daniel Raper et al.
TRENDS IN NEUROSCIENCES (2016)
The Role of the Tumor vasculature in the Host immune Response: implications for Therapeutic Strategies Targeting the Tumor Microenvironment
Shona A. Hendry et al.
FRONTIERS IN IMMUNOLOGY (2016)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Structural and functional features of central nervous system lymphatic vessels
Antoine Louveau et al.
NATURE (2015)
Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases
A. S. Berghoff et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Yoshinari Asaoka et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients
C. Collen et al.
ANNALS OF ONCOLOGY (2014)
Restoration of natural killer cell cytotoxicity by VEGFR-3 inhibition in myelogenous leukemia
Ji Yoon Lee et al.
CANCER LETTERS (2014)
HIF Transcription Factors, Inflammation, and Immunity
Asis Palazon et al.
IMMUNITY (2014)
Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy
N. A. Rizvi et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Radiologic and histologic consequences of radiosurgery for brain tumors
Ahmed Alomari et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Mechanisms of resistance to anti-angiogenesis therapies
Sandy Giuliano et al.
BIOCHIMIE (2013)
Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
Priti S. Hegde et al.
CLINICAL CANCER RESEARCH (2013)
Advances in therapy for melanoma brain metastases
Jaclyn C. Flanigan et al.
CLINICS IN DERMATOLOGY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
On the Merits and Limitations of Whole-Brain Radiation Therapy
Atif J. Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Invasion patterns in brain metastases of solid cancers
Anna S. Berghoff et al.
NEURO-ONCOLOGY (2013)
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
Paul W. Sperduto et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Radiation-induced cognitive impairment-from bench to bedside
Dana Greene-Schloesser et al.
NEURO-ONCOLOGY (2012)
Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data
Faith G. Davis et al.
NEURO-ONCOLOGY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Andrea Facciabene et al.
NATURE (2011)
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes
C. Alfaro et al.
BRITISH JOURNAL OF CANCER (2009)
Gamma Knife surgery for the treatment of melanoma metastases: the effect of intratumoral hemorrhage on survival
Andy J. Redmond et al.
JOURNAL OF NEUROSURGERY (2008)
Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer - Clinical implications for the subsequent management of the brain
Allen M. Chen et al.
CANCER (2007)
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
JE Ohm et al.
BLOOD (2003)
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
TJ Curiel et al.
NATURE MEDICINE (2003)
Share Paper
